Eventide Asset Management - Q3 2020 holdings

$5.11 Billion is the total value of Eventide Asset Management's 142 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A/Ssponsored adr$263,864,000
+4.3%
1,709,8480.0%5.16%
-6.0%
EXAS  EXACT SCIENCES CORP$177,393,000
+17.3%
1,740,0000.0%3.47%
+5.6%
BHVN  BIOHAVEN PHARMACTL HLDG CO L$115,962,000
-11.1%
1,783,7610.0%2.27%
-19.9%
MTD  METTLER TOLEDO INTERNATIONAL$87,883,000
+19.9%
91,0000.0%1.72%
+7.9%
MYOK  MYOKARDIA INC$84,661,000
+41.1%
621,0000.0%1.66%
+27.1%
WCN  WASTE CONNECTIONS INC$83,455,000
+10.7%
804,0000.0%1.63%
-0.3%
KRTX  KARUNA THERAPEUTICS INC$69,671,000
-30.6%
901,0770.0%1.36%
-37.5%
ASML  ASML HOLDING N V$63,514,000
+0.3%
172,0000.0%1.24%
-9.7%
PLRX  PLIANT THERAPEUTICS INC$61,693,000
-30.2%
2,838,1250.0%1.21%
-37.1%
COLL  COLLEGIUM PHARMACEUTICAL INC$50,550,000
+19.0%
2,427,9760.0%0.99%
+7.1%
MRTX  MIRATI THERAPEUTICS INC$49,981,000
+45.4%
301,0000.0%0.98%
+30.9%
APTV  APTIV PLC$49,232,000
+17.7%
537,0000.0%0.96%
+5.9%
BPMC  BLUEPRINT MEDICINES CORP$42,827,000
+18.8%
462,0000.0%0.84%
+7.0%
GWPH  GW PHARMACEUTICALS PLCads$42,445,000
-20.7%
436,0000.0%0.83%
-28.5%
RCKT  ROCKET PHARMACEUTICALS INC$35,433,000
+9.2%
1,550,0000.0%0.69%
-1.6%
TPTX  TURNING POINT THERAPEUTICS I$33,459,000
+35.3%
383,0000.0%0.66%
+21.7%
VCYT  VERACYTE INC$30,216,000
+25.4%
930,0000.0%0.59%
+12.8%
GBT  GLOBAL BLOOD THERAPEUTICS IN$29,500,000
-12.7%
535,0000.0%0.58%
-21.4%
KALA  KALA PHARMACEUTICALS INC$25,875,000
-28.6%
3,450,0000.0%0.51%
-35.7%
AVRO  AVROBIO INC$24,807,000
-25.4%
1,905,3070.0%0.49%
-32.8%
CGNX  COGNEX CORP$23,371,000
+9.0%
359,0000.0%0.46%
-1.9%
OKTA  OKTA INCcl a$23,096,000
+6.8%
108,0000.0%0.45%
-3.8%
KALV  KALVISTA PHARMACEUTICALS INC$21,151,000
+4.0%
1,680,0000.0%0.41%
-6.3%
CRNX  CRINETICS PHARMACEUTICALS IN$21,107,000
-10.6%
1,347,0000.0%0.41%
-19.5%
AY  ATLANTICA SUSTAINABLE INFR P$21,057,000
-1.7%
736,0000.0%0.41%
-11.6%
SGEN  SEATTLE GENETICS INC$20,058,000
+15.2%
102,5000.0%0.39%
+3.7%
STRO  SUTRO BIOPHARMA INC$19,959,000
+29.5%
1,985,9750.0%0.39%
+16.7%
XPO  XPO LOGISTICS INC$18,625,000
+9.6%
220,0000.0%0.36%
-1.1%
ISRG  INTUITIVE SURGICAL INC$17,739,000
+24.5%
25,0000.0%0.35%
+11.9%
RGEN  REPLIGEN CORP$17,557,000
+19.4%
119,0000.0%0.34%
+7.5%
REGN  REGENERON PHARMACEUTICALS$17,297,000
-10.2%
30,9000.0%0.34%
-19.1%
PHAT  PHATHOM PHARMACEUTICALS INC$16,502,000
+11.4%
450,0000.0%0.32%
+0.3%
XLRN  ACCELERON PHARMA INC$16,081,000
+18.1%
142,9000.0%0.32%
+6.4%
MGTA  MAGENTA THERAPEUTICS INC$16,046,000
-9.5%
2,359,6460.0%0.31%
-18.4%
XENE  XENON PHARMACEUTICALS INC$14,104,000
-11.7%
1,274,1000.0%0.28%
-20.5%
ALLK  ALLAKOS INC$13,032,000
+13.3%
160,0000.0%0.26%
+2.0%
DCPH  DECIPHERA PHARMACEUTICALS IN$12,466,000
-14.1%
243,0000.0%0.24%
-22.5%
XNCR  XENCOR INC$11,637,000
+19.8%
300,0000.0%0.23%
+8.1%
CIEN  CIENA CORP$10,597,000
-26.7%
267,0000.0%0.21%
-34.1%
GLPG  GALAPAGOS NVspon adr$7,237,000
-28.1%
51,0000.0%0.14%
-35.2%
FENC  FENNEC PHARMACEUTICALS INC$6,787,000
-27.4%
1,120,0000.0%0.13%
-34.5%
ARVN  ARVINAS INC$5,430,000
-29.6%
230,0000.0%0.11%
-36.9%
 EXACT SCIENCES CORPnote 1.000% 1/1$3,743,000
+13.3%
2,411,0000.0%0.07%
+1.4%
ETTX  ENTASIS THERAPEUTICS HLDGS I$1,705,000
-31.1%
879,5410.0%0.03%
-38.9%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-11-13
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q3 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings